pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Cancer Program · news · pharmadog
← back to Cancer Program
News mentioning Cancer Program
116
stories
Aug 17, 26
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
Aug 13, 26
PDS halts work on phase 3 cancer therapy to focus on colorectal contender
fiercebiotech
Aug 6, 26
Replimune rebounds to win FDA approval of melanoma drug
biopharma dive
Aug 5, 26
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
Aug 5, 26
5 NextGen winners who went public this year (and which ones are hiring)
biospace
Aug 4, 26
Merck plans trial of sac-TMT combo with Keytruda in lung cancer
endpoints
Aug 4, 26
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
Aug 4, 26
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
Aug 4, 26
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
fiercebiotech
Jul 30, 26
Replimune melanoma drug wins support of FDA panel
biopharma dive
Jul 29, 26
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
Jul 28, 26
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
biospace
Jul 27, 26
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 24, 26
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
Jul 23, 26
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
biospace
Jul 22, 26
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 16, 26
Merck wins first approval of a PCSK9 cholesterol pill
biopharma dive
Jul 15, 26
Merck ADC, in China study, shows potential to replace chemo in lung cancer
biopharma dive
Jul 15, 26
STAT+: Celcuity’s breast cancer drug approved, its first
stat
Jul 15, 26
Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
biospace
Jul 14, 26
STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last year
stat
Jul 13, 26
Agenus surges on study pivot; Apnimed lines up an IPO
biopharma dive
Jul 2, 26
Roche KRAS drug succeeds in head-to-head lung cancer study
biopharma dive
Jul 1, 26
Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
biopharma dive
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 15, 26
Medicare drug price rule may target under-the-skin Keytruda and Opdivo
biopharma dive
Jun 12, 26
Merck brings Welireg-Keytruda combo to treat kidney cancer
endpoints
Jun 11, 26
Summit pulls $500M share sale a day after announcing it
biopharma dive
Jun 9, 26
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
biopharma dive
← prev
page 3 of 4
next →
